Cancer patients frequently suffer from fatigue, a complex syndrome associated with loss of muscle mass, weakness, and depressed mood. Cancer-related fatigue (CRF) can be present at the time of diagnosis, during treatment, and persists for years after treatment. CRF negatively influences quality of life, limits functional independence, and is associated with decreased survival in patients with incurable disease. Currently there are no effective treatments to reduce CRF. The aim of this study was to use a mouse model of tumor growth and discriminate between two main components of fatigue: loss of muscle mass/function and altered mood/motivation. Here we show that tumor growth increased fatigue-and depressivelike behaviors, and reduced body and muscle mass. Decreased voluntary wheel running activity (VWRA) and increased depressive-like behavior in the forced swim and sucrose preference tests were evident in tumor-bearing mice within the first two weeks of tumor growth and preceded the loss of body and muscle mass. At three weeks, tumor-bearing mice had reduced grip strength but this was not associated with altered expression of myosin isoforms or impaired contractile properties of muscles. These increases in fatigue and depressive-like behaviors were paralleled by increased expression of IL-1b mRNA in the cortex and hippocampus. Minocycline administration reduced tumor-induced expression of IL-1b in the brain, reduced depressive-like behavior, and improved grip strength without altering muscle mass. Taken together, these results indicate that neuroinflammation and depressed mood, rather than muscle wasting, contribute to decreased voluntary activity and precede major changes in muscle contractile properties with tumor growth.
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Introduction
Fatigue is the most common symptom reported by cancer patients before and during treatment, and can continue for years after completion of treatment (Bower and Lamkin, 2013; Husson et al., 2013; Minton et al., 2012) . It often co-occurs with depression, (Bower et al., 2011; Kim et al., 2012; Pertl et al., 2013 ) and reduces quality of life (Vissers et al., 2013) . However, the cause of cancer-related fatigue (CRF) is unknown (Berger et al., 2012) and there are no effective treatments (Bower and Lamkin, 2013) .
Mounting evidence indicates that CRF and depressed mood are associated with elevated serum levels of pro-inflammatory mediators, including C-reactive protein (Pertl et al., 2013) and cytokines such as tumor necrosis factor-alpha (TNFa), interleukin (IL)-1b and IL-6 (Saligan and Kim, 2012; Wood and Weymann, 2013) . These cytokines are likely produced by the tumor and host tissues in response to tumor growth or anti-tumor treatments (Wang et al., 2012) . Pro-inflammatory cytokines increase expression of biomarkers of autophagy and the ubiquitin-proteasome pathway in skeletal muscle which reduce muscle mass (Fearon et al., 2012; Sandri, 2013; Toledo et al., 2011) . The loss of muscle mass, or sarcopenia, can be seen even before cancer treatment (Baracos et al., 2010; Cao et al., 2010) and likely explains patient complaints of exhaustion associated with physical activity and muscle weakness (Hofman et al., 2007) .
